|
Dr. Johnston joined Cellumen in 2005. Prior to joining Cellumen, she was the Director of Lead Generation Biology at Eli Lilly and Co. from 2001 to 2005, responsible for Assay Development and High Throughput Screening at Lilly's Center of Excellence in Research Triangle Park, NC. From 1993 - 2001 Dr. Johnston served as Head of the Assay Development function at Sphinx Pharmaceuticals which was acquired by Lilly in 1994. Dr. Johnston received her doctoral training in Cell Biology from Duke University Medical Center and pursued post-doctoral training at the Howard Hughes Medical Institute in Dallas. Dr. Johnston serves on the Lead Development Team of the NIMH-funded Spinal Muscular Atrophy Project, the HTS Steering Committee of the National Toxicology Project, the NIH Special Emphasis Panel for HTS in the MLSCN, and is an ad hoc reviewer for several NIMH study sections and journals. | 